PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics


PHATHOM PHARMACEUTICALS, INC. (PHAT): $7.44

0.03 (+0.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHAT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHAT Stock Price Chart Interactive Chart >

Price chart for PHAT

PHAT Price/Volume Stats

Current price $7.44 52-week high $38.26
Prev. close $7.41 52-week low $6.74
Day low $7.30 Volume 157,400
Day high $7.62 Avg. volume 188,687
50-day MA $12.24 Dividend yield N/A
200-day MA $20.55 Market Cap 290.70M

PHATHOM PHARMACEUTICALS, INC. (PHAT) Company Bio


Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.


PHAT Latest News Stream


Event/Time News Detail
Loading, please wait...

PHAT Latest Social Stream


Loading social stream, please wait...

View Full PHAT Social Stream

Latest PHAT News From Around the Web

Below are the latest news stories about Phathom Pharmaceuticals Inc that investors may wish to consider to help them evaluate PHAT as an investment opportunity.

How Western Digital’s Setback Actually Could Boost Its Shares

Prices for NAND flash memory might rise after contamination problem that temporarily will reduce output. Also, Wall Street opinions on Pfizer, Check Point Software, Kite Realty Group, Linde, and Phathom Pharmaceuticals.

Yahoo | February 12, 2022

Needham Thinks Phathom Pharmaceuticals’ Stock is Going to Recover

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $55.00. The company's shares closed last Wednesday at $17.30, close to its 52-week low of $14.04. According to TipRanks.com, Stringer has 0 stars on 0-5 stars ranking scale with an average return of -19.4% and a 24.8% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Rhythm Pharmaceuticals, and Vertex Pharmaceuticals. Phathom Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $55.00.

Christine Brown on TipRanks | February 10, 2022

Phathom Pharma''s Digestive Disease Candidate Meets Primary Goal In Mid-Stage Study

Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episodic heartburn in non-erosive gastroesophageal reflux disease (NERD). All three vonoprazan dose levels met the primary endpoint and were statistically significant compared to placebo in the study. Within three hours, vonoprazan … Full story available on Benzinga.com

Benzinga | February 10, 2022

Phathom says mid-stage study for vonoprazan in gastroesophageal reflux met main goal

Announcing topline data from its PHALCON-NERD trial for vonoprazan, Phathom Pharmaceuticals (NASDAQ:PHAT) said that the experimental on-demand therapy for episodic heartburn met the main goal in subjects with non-erosive gastroesophageal reflux disease (NERD). In reaction, Phathom (PHAT) shares have added ~9% in the post-market. In the Phase 2 study, vonoprazan achieved the...

Seeking Alpha | February 9, 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

FLORHAM PARK, N.J., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported positive topline results from PHALCON-NERD, a Phase 2 study evaluating three dose levels of vonoprazan (10 mg, 20 mg, and 40 mg) as an on-demand therapy for relief of episodic heartburn in subjects with non-erosive gastroesophageal reflux disease (NERD). In this double-blind, placebo-controlled study, all three vonoprazan dose levels successfully met the primary endpoint and were statistically significant (p<0.0001) when compared to placebo.

GlobeNewswire | February 9, 2022

Read More 'PHAT' Stories Here

PHAT Price Returns

1-mo -44.06%
3-mo -59.78%
6-mo -60.30%
1-year -78.95%
3-year N/A
5-year N/A
YTD -62.18%
2021 -40.79%
2020 6.68%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4624 seconds.